Temoside 250mg 5 Capsules

babies: it is not applicable. lactation mother: it is unsafe because studies have shown limited evidence of side effects to the baby. pregnancy: consult your doctor because studies have shown evidence of harmful effects on the developing baby. driving: avoid driving while taking this medication as it may cause drowsiness, sleepiness, and dizziness.
do not drive if these symptoms occur. alcohol: consult your doctor because no studies have shown evidence whether it is safe to consume alcohol or not. kidney: safe if prescribed by your doctor because studies have shown evidence of limited evidence in patients with kidney disease. liver: use this medication with caution in patients with liver disease.
dose adjustment must be necessary..

Nausea Vomiting Headache Alopecia Constipation Rashes Hemiparesis Memory loss Loss of appetite Weakness Viral infection Fever Insomnia Diarrhea.

temoside capsule penetrates brain tissue and works by damaging the genetic material (dna and rna) of cancer cells and stops their growth and reproduction..

If you miss a dose, take temoside capsule as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• use effective contraception while taking temoside capsule medicine to avoid pregnancy. • temoside capsule increases the risk of bleeding. be careful when shaving, trimming fingernails or toenails, or using pointed objects. • your doctor may perform regular blood tests to monitor your blood cell count and liver function. • tell your doctor if you develop a severe rash, fever, chills, headache, and shortness of breath during treatment. • advise the patient with nausea or vomiting to take medication on an empty stomach or at bedtime.
• side effects may include alopecia, fatigue, nausea, vomiting, headache, constipation, anorexia, and convulsions..

serious • temozolomide + deferiprone: concurrent use leads to increased toxicity. • temozolomide + tofacitinib: concurrent use leads to increase toxicity and risk of infection. monitor closely • temozolomide + acalabrutinib: concurrent use leads to an increase in the risk of myelosuppressive effects. • temozolomide + hydroxyurea: concurrent use leads to an increase in the risk of myelosuppressive effects. • temozolomide + valproic acid: concurrent use leads to an increase in temozolomide levels by decreasing valproic acid.
.